跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
新聞/媒體
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
溫 有汶
副教授
,
生物醫學系(含學士班、臨床試驗與評估碩士班)
https://orcid.org/0000-0002-7979-3845
電子郵件
D000005946
cgu.edu
tw
h-index
h10-index
h5-index
1851
引文
26
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1048
引文
18
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
309
引文
9
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2001
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(9)
研究產出
(110)
相近領域學者
(6)
指導學生論文
(12)
指紋
查看啟用 Yu-Wen Wen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Patient
100%
Inpatient
55%
Squamous Cell Carcinoma
44%
Chemoradiotherapy
40%
Esophageal Squamous Cell Carcinoma
40%
Oral Cavity
35%
Analysis
30%
Therapeutic Procedure
29%
Overall Survival
26%
Esophagectomy
21%
Cost-Effectiveness Analysis
17%
Surgery
17%
Malignant Neoplasm
16%
Health Care Cost
16%
Cohort Analysis
16%
Esophageal Cancer
15%
Disease Specific Survival
14%
Neoplasm
14%
Combination Therapy
14%
Survival Rate
13%
Hospital
13%
Learning Curve
13%
Hazard Ratio
12%
Cardiovascular System
11%
Survival
11%
Association
11%
Surgical Margin
10%
Acetylsalicylic Acid
10%
Surgeon
10%
Proton-Pump Inhibitor
9%
Antiplatelet
9%
Recurrent Disease
9%
Randomized Controlled Trial
9%
Incidence
8%
Experience
8%
Health
8%
Clopidogrel
8%
Adjuvant Therapy
8%
Retroperitoneal Lymph Node Dissection
8%
Life
7%
Disease
7%
Prognosis
7%
Age
7%
Neck Dissection
6%
Outpatient
6%
Development
6%
Clinical Stage
6%
Diagnosis
6%
Computer Assisted Tomography
6%
Endoscopic Biopsy
6%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
24%
Chemoradiation Therapy
17%
Drug
16%
Esophageal Squamous Cell Carcinoma
15%
Thiazolidinedione
14%
Anticoagulant Agent
12%
Acetylsalicylic Acid
12%
Proton Pump Inhibitor
12%
Survival
11%
Clopidogrel
10%
Overall Survival
10%
Diabetes Mellitus
10%
Death
9%
Squamous Cell Carcinoma
8%
Alendronic Acid
8%
Gastrointestinal Hemorrhage
7%
Diseases
7%
Incidence
6%
Mortality
6%
Acute Heart Infarction
6%
Neoplasm
6%
Complication
6%
Non-Steroidal Anti-Inflammatory Drug
5%
Breast Cancer
5%
Granulocyte Colony Stimulating Factor
5%
Pneumococcus Vaccine
5%
Polypharmacy
5%
Non Insulin Dependent Diabetes Mellitus
5%
Cholinergic Receptor Blocking Agent
5%
Femur Fracture
5%
Celecoxib
5%
Esophagus Cancer
5%
Cardiovascular Disease
5%
Nursing and Health Professions
Clinical Outcome
17%
Cohort Analysis
15%
Patient
12%
Confidence Interval
9%
Diseases
8%
Death
8%
Control
7%
Odds Ratio
7%
Mortality
7%
Cost Effectiveness Analysis
5%
Esophageal Squamous Cell Carcinoma
5%
Alendronic Acid
5%
Squamous Cell Carcinoma
5%
Cholinergic Receptor Blocking Agent
5%
Inpatient
5%
Overall Survival
5%
Propensity Score
5%
Incidence
5%
Chemoradiotherapy
5%
